RxDoctor Payments Data

Alan Lerman, MD

Gastroenterology · Binghamton, NYNPI 1306886981

Payments from drug & device makers

$1,008in general payments, 2019–2025

Across 38 payments — averaging $26.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$332
  • Takeda Pharmaceuticals U.S.A., Inc.$248
  • Johnson & Johnson$164
  • Intercept Pharmaceuticals, Inc.$63
  • Gilead$57
  • Pfizer$41
  • plus $103 from 5 others

What the payments were for

  • Food & beverage$96496%
  • Education$454%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,008 in reported general payments places this provider in the 35th percentile of 1,682 gastroenterology providers in New York.

See all gastroenterology providers in New York

Medicare billing

Part B allowed, 2024
$51,669
Medicare patients
261
Services billed
513

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LinzessLinaclotide55$33,089
Mesalamine27$12,510
Ursodiol13$3,847
Budesonide EcBudesonide11$2,220
Mercaptopurine15$1,943
CholestyramineCholestyramine (With Sugar)21$1,415
Vancomycin Hcl24$1,371
Cholestyramine LightCholestyramine11$1,128
Pantoprazole Sodium64$763
Omeprazole86$748
Dicyclomine Hcl12$499
Gavilyte-CPeg3350/Sod Sulf,bicarb,cl/Kcl30$490
Amitriptyline Hcl29$329
Gavilyte-GPeg3350/Sod Sulf,bicarb,cl/Kcl16$201
Famotidine38$182

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLinzess$332$33,08955 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 1,682 gastroenterology providers in New York.

Other gastroenterology in Binghamton

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →